Inflarx Stock Price, News & Analysis

InflaRx (Nasdaq: IFRX) provided updated analyses from its terminated Phase 3 study of vilobelimab in ulcerative pyoderma gangrenosum (PG). The trial was stopped early for futility after enrolling 54 patients (30 completed 6 months). The prespecified primary endpoint (complete target ulcer closure on two consecutive visits) favored vilobelimab 20.8% vs placebo 16.7% (p=NS). Post-hoc analyses showed statistically significant reductions in target ulcer volume: MMRM percent change overall -45.4% (p=0.0428) and weekly differences from Week 14 to 26 (e.g., Week 26 -63.2%, p=0.0122); ANCOVAs for volume and area were p=0.0111 and p=0.0072. Safety was generally well tolerated with similar serious related TEAEs (6.3% vs 4.5%). InflaRx plans FDA discussions and expects future PG work would require a partner.

InflaRx (Nasdaq: IFRX) announced the World Health Organization has granted the international nonproprietary name izicopan for its oral C5aR inhibitor formerly known as INF904; the name will be published in the WHO recommended INN list.

Izicopan has shown tolerability in first‑in‑human single doses (3–240 mg) and multiple doses (30 mg once daily to 90 mg twice daily), pharmacokinetic/pharmacodynamic support with a ≥90% blockade of C5a‑induced neutrophil activation over 14 days, and topline Phase 2a signals of clinical activity in hidradenitis suppurativa and chronic spontaneous urticaria.

InflaRx (Nasdaq: IFRX) reported positive topline Phase 2a results for oral C5aR inhibitor INF904 in hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU) on Nov 10, 2025. Data from 29 HS and 30 CSU patients showed rapid reductions in lesion counts and symptoms over 4 weeks with durable effects at Week 8.

Key 4-week signals: HiSCR50 28% (all doses), HiSCR50 Week 8 44% (n=25); AN change −5.1 (all doses); dT100 29%; NRS30 pain response 66%; CSU UAS7 change −10.4 (all doses) and −15.4 in severe CSU (60 mg). No serious adverse events reported. Company targets Phase 2b initiation in HS in 2026 and continues partner discussions.

InflaRx (Nasdaq: IFRX) expects to report topline Phase 2a clinical data for oral C5aR inhibitor INF904 in hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU) in a pre-market press release on November 10, 2025.

The company will host a webcast and slide presentation on November 10, 2025 at 8:00 AM EST / 2:00 PM CET and also expects to publish third quarter 2025 financial results via Form 6-K the same day pre-market.

InflaRx (Nasdaq: IFRX) will participate in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference in Boston, MA from November 10–12, 2025. The company will appear in a fireside chat on November 11 at 2:30 PM ET and will hold one-on-one investor meetings the same day. A live stream and replay link for the fireside chat will be provided.

InflaRx is a biopharmaceutical company focused on anti-inflammatory therapeutics that target the complement system, developing vilobelimab (intravenous anti-C5a antibody) and INF904 (oral C5a receptor inhibitor). The company has offices in Jena and Munich, Germany, and Ann Arbor, MI.

InflaRx (NASDAQ: IFRX), a biopharmaceutical company focused on anti-inflammatory therapeutics, has successfully regained compliance with Nasdaq's minimum bid price requirement. The company maintained a closing bid price of $1.00 or higher for 10 consecutive business days from August 27 to September 10, 2025.

InflaRx specializes in developing inhibitors of the complement activation factor C5a and its receptor. Their key product is vilobelimab, an intravenous first-in-class anti-C5a monoclonal antibody, alongside INF904, an oral small molecule inhibitor. The company, founded in 2007, operates from offices in Jena and Munich, Germany, and Ann Arbor, Michigan.

InflaRx (NASDAQ:IFRX), a biopharmaceutical company focused on anti-inflammatory therapeutics, has announced its participation in two major investor conferences in September 2025. The company will present at the Cantor Global Healthcare Conference (September 3-5) with a fireside chat on September 4th at 9:10 AM ET, and at the H.C. Wainwright 27th Annual Global Investment Conference (September 8-10) with a presentation on September 9th at 3:30 PM ET.

InflaRx specializes in developing inhibitors of the complement activation factor C5a and its receptor. Their lead product, vilobelimab, is an intravenous anti-C5a monoclonal antibody, and they are also developing INF904, an oral small molecule C5a receptor inhibitor.

InflaRx (NASDAQ:IFRX) reported Q2 2025 financial results and provided key updates on its pipeline. The company's cash position stands at €53.7 million, with runway extending into 2027. Key developments include anticipated INF904 Phase 2a data in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) expected by early November 2025.

Financial highlights show a net loss of €23.0 million (€0.35 per share) for H1 2025. The company's partner Staidson BioPharmaceuticals reported favorable Phase 1/2 results for BDB-001 in ANCA-associated vasculitis, planning to advance to Phase 3. The previously announced Phase 3 pyoderma gangrenosum trial was stopped due to futility, with full data analysis expected later this year.

Additionally, enrollment began in the BARDA-funded JUST BREATHE Phase 2 platform trial investigating vilobelimab for acute respiratory distress syndrome (ARDS). The company maintains EU approval for GOHIBIC (vilobelimab) in SARS-CoV-2-induced ARDS and is pursuing commercial partnerships.

InflaRx (NASDAQ: IFRX), a biopharmaceutical company focused on anti-inflammatory therapeutics, has scheduled its second quarter 2025 financial results announcement for August 7, 2025, before market opening. No earnings call is planned.

The company specializes in developing therapeutics targeting the complement system, particularly the C5a inflammatory mediator. Their key developments include vilobelimab, an intravenous anti-C5a monoclonal antibody, and INF904, an oral small molecule C5a receptor inhibitor. InflaRx maintains operations in Jena and Munich, Germany, and Ann Arbor, Michigan, USA.